Jun 4 |
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
|
May 28 |
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
|
May 24 |
FSD Pharma Provides Corporate Update
|
May 16 |
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
|
May 7 |
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
|
Apr 30 |
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
|
Apr 22 |
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
|
Apr 17 |
FSD Pharma expands pipeline investigation to include weight loss and liver health products
|
Apr 17 |
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
|
Apr 15 |
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
|